Introduction of traditional Chinese medicine industry

1, favorable policies frequently support the development of Chinese medicine industry.

In recent years, China has promulgated many policies to promote the development of Chinese medicine industry. Especially under the background of prevention and control of epidemic normalization in COVID-19, the traditional medical value of Chinese medicine has become more and more precious, and the state and society have paid more and more attention to the Chinese medicine industry. In recent years, China's traditional Chinese medicine industry related policies are:

2. Chinese patent medicine occupies half of the Chinese medicine market.

Traditional Chinese medicine has certain innate advantages in treating intractable diseases and chronic diseases. During the Tenth Five-Year Plan period, a series of policies were issued at the national level to increase the clinical application of traditional Chinese medicine. With the support of national policies and the promotion of clinical departments, the overall scale of Chinese medicine industry has grown steadily in recent years. According to the data of the Ministry of Industry and Information Technology and the National Bureau of Statistics, in 20021year, the overall regulatory scale of the Chinese medicine market exceeded 900 billion yuan, of which the income from the main business of Chinese medicine was194.5 billion yuan, an increase of 8.2% compared with179.7 billion yuan in 2020; The main business income of proprietary Chinese medicines was 486.2 billion yuan, an increase of11.8% compared with 434.7 billion yuan in 2020; The main business income of Chinese herbal pieces is 205.7 billion yuan, increasing by180.9 billion yuan in 2020. In recent years, the emerging Chinese medicine formula granules have reached a market scale of 53.3 billion yuan, accounting for nearly 6% of the whole industry. Formulated granules have a good development momentum and will be a new growth point for the whole industry in the future.

3.R&D and innovation fever of traditional Chinese medicine industry.

During the Tenth Five-Year Plan period, China intensively promulgated a number of policies and regulations related to drug innovation, which created a better market environment for new drug research and development, and the innovation achievements of traditional Chinese medicine began to blowout. 202 1 There are 12 innovative Chinese medicine (including Qingfei Jiedu Granule, Huashi Jiedu Granule and Xuanfei Jiedu Granule, which were approved urgently for COVID-19's treatment), exceeding the sum of the number listed in the previous five years.

In 2022, with the continuous encouragement of national policies, Chinese medicine enterprises were enthusiastic about R&D, and a number of new Chinese medicine products with reference to the Catalogue of Ancient Classic Prescriptions were approved, marking a new situation in the listing of new Chinese medicine products. In 2022, the State Administration of Pharmaceutical Products approved seven innovative Chinese medicines (excluding raw materials). According to the data in Minenet, there are more than 60 kinds of new Chinese medicine 1 in the research and development stage. In the future, with the emergence of batches of innovative Chinese medicines with remarkable curative effects, the market of innovative Chinese medicines will continue to expand.

For more research and analysis of this industry, please refer to the Analysis Report on Market Foresight and Investment Strategic Planning of Chinese Medicine Industry in China by Forward-looking Industry Research Institute.